Proton therapy in a pediatric patient with stage III Hodgkin lymphoma

Figures & data

Table I. Mean dose to organs at risk.

	3DCRT	IMRT	PT*	3DCRT-PT		IMRT-PT		3DCRT-IMRT
	Mean dose	Mean dose	Mean dose	RR	AR (Gy)	RR	AR (Gy)	RR	AR (Gy)
Body (J)**	185	201	101	45%	84	50%	100	-8%	-16
Breasts (Gy)	8.2	7.5	1.8	78%	6.4	76%	5.7	9%	0.7
Heart (Gy)	16.7	16	12.3	26%	4.4	23%	3.7	4%	0.7
Lungs (Gy)	12.6	14.1	9.4	25%	3.2	33%	4.7	-12%	-1.5
Stomach (Gy)	21.7	19.9	12.2	44%	9.5	39%	7.7	8%	1.8
Bowel (Gy)	11.2	10.2	4.7	58%	6.5	54%	5.5	9%	1
Esophagus (Gy)	18	17.9	16.2	10%	1.8	9%	1.7	1%	0.1
Liver (Gy)	3.8	6.2	0.3	92%	3.5	95%	5.9	-63%	-2.4

AR, absolute reduction; Gy, Gray; IMRT, intensity-modulated radiation therapy; J, Joule; RR, relative reduction; 3DCRT, three-dimensional conformal radiotherapy.

*PT represented in terms of relative biologic effectiveness.

**Body reflects integral dose measured in joules.

Figure 1. Comparison of the dose distribution of (A) three-dimensional conformal radiotherapy (3DCRT), (B) intensity-modulated radiotherapy (IMRT), and (C) proton therapy (PT) plans. The clinical target volume (CTV), breasts, heart, and liver are outlined in red, pink, green and yellow, respectively.